Search Results

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to develop long-acting versions of molecules against GLP-1 and other incretins.

Juvena Therapeutics today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161. JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.

Juvena Therapeutics pulled in $41 million in Series A financing to advance research into the therapeutic potential of secreted proteins to target chronic and age-related diseases.

Juvena Therapeutics , Inc. announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies.

Juvena Therapeutics, Inc. announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million.

Juvena Therapeutics today announced that the company has been awarded a highly competitive translational grant from the California Institute of Regenerative Medicine (CIRM), totaling $3,906,376.